Highlights IN8bio, Inc.

Equities

INAB

US45674E1091

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-18 EDT			5-day change	1st Jan Change
1 ^USD	0.00%		-31.97%	-27.54%

06-14	JonesTrading Adjusts IN8bio's Price Target to $6.50 From $5, Keeps Buy Rating	MT
06-13	IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100	06-13	CI
IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting	06-03	CI
IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme	05-24	MT
In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024	05-13	CI
IN8bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma	04-30	CI
Top Premarket Gainers	04-10	MT
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	04-09	CI
IN8bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	03-05	CI
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	02-14	CI
IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia	12-11	CI
IN8bio, Inc.?s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma	11-20	CI
IN8bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting	11-06	CI
IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell Platform at the Society for Immunotherapy of Cancer 38th Annual Meeting	11-03	CI
IN8bio, Inc. to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology Annual Meeting	11-02	CI
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma	23-10-12	CI
IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting	23-09-29	CI
IN8bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IN8bio, Inc.

Equities

INAB

US45674E1091

Highlights

Filters